(Q39866378)

15 September 2017

title

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma (English)

1 reference

15 September 2017

main subject

phase III clinical trial

0 references

1 reference

1

Howard L Kaufman

1 reference

15 September 2017

Steven D Bines

2

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

15 September 2017

1 reference

15 September 2017

volume

6

1 reference

15 September 2017

issue

6

1 reference

15 September 2017

page(s)

941-949

1 reference

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

15 September 2017

cites work

1 reference

Management of cutaneous melanoma

21 January 2018

1 reference

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

Immunotherapy of melanoma: a critical review of current concepts and future strategies

21 January 2018

1 reference

Recent advances and hurdles in melanoma immunotherapy.

21 January 2018

1 reference

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

Viral vaccines for cancer immunotherapy

21 January 2018

1 reference

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

21 January 2018

1 reference

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

21 January 2018

1 reference

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response.

21 January 2018

1 reference

The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain

21 January 2018

1 reference

Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein

21 January 2018

1 reference

GM-CSF gene-transduced tumor vaccines

21 January 2018

1 reference

Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2.

21 January 2018

1 reference

Biological therapy with oncolytic herpesvirus.

21 January 2018

1 reference

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

Administration of cyclophosphamide changes the immune profile of tumor-bearing mice

21 January 2018

1 reference

Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide

21 January 2018

1 reference

Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide

21 January 2018

1 reference

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

21 January 2018

1 reference

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

21 January 2018

1 reference

Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.66

1 reference

15 September 2017

1 reference